BridgeBio Pharma, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported sales was USD 1.75 million compared to USD 1.87 million a year ago. Net loss was USD 168.15 million compared to USD 137.59 million a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
29 USD | -1.76% | +0.33% | -28.05% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.05% | 5.52B | |
-3.15% | 89.69B | |
+2.50% | 41.34B | |
-12.44% | 33.72B | |
+62.74% | 26.11B | |
-20.63% | 14.63B | |
-8.79% | 12.84B | |
-12.34% | 11.66B | |
-43.92% | 11.52B | |
+4.27% | 8.92B |
- Stock Market
- Equities
- BBIO Stock
- News BridgeBio Pharma, Inc.
- BridgeBio Pharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023